These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
452 related articles for article (PubMed ID: 28303528)
1. Human mass balance study and metabolite profiling of van Andel L; Zhang Z; Lu S; Kansra V; Agarwal S; Hughes L; Tibben MM; Gebretensae A; Lucas L; Hillebrand MJX; Rosing H; Schellens JHM; Beijnen JH Invest New Drugs; 2017 Dec; 35(6):751-765. PubMed ID: 28303528 [TBL] [Abstract][Full Text] [Related]
2. Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a van Andel L; Rosing H; Zhang Z; Hughes L; Kansra V; Sanghvi M; Tibben MM; Gebretensae A; Schellens JHM; Beijnen JH Cancer Chemother Pharmacol; 2018 Jan; 81(1):39-46. PubMed ID: 29043410 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial. Fabbro M; Moore KN; Dørum A; Tinker AV; Mahner S; Bover I; Banerjee S; Tognon G; Goffin F; Shapira-Frommer R; Wenham RM; Hellman K; Provencher D; Harter P; Vázquez IP; Follana P; Pineda MJ; Mirza MR; Hazard SJ; Matulonis UA Gynecol Oncol; 2019 Mar; 152(3):560-567. PubMed ID: 30638768 [TBL] [Abstract][Full Text] [Related]
4. FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy. Ison G; Howie LJ; Amiri-Kordestani L; Zhang L; Tang S; Sridhara R; Pierre V; Charlab R; Ramamoorthy A; Song P; Li F; Yu J; Manheng W; Palmby TR; Ghosh S; Horne HN; Lee EY; Philip R; Dave K; Chen XH; Kelly SL; Janoria KG; Banerjee A; Eradiri O; Dinin J; Goldberg KB; Pierce WF; Ibrahim A; Kluetz PG; Blumenthal GM; Beaver JA; Pazdur R Clin Cancer Res; 2018 Sep; 24(17):4066-4071. PubMed ID: 29650751 [TBL] [Abstract][Full Text] [Related]
5. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities. Moore KN; Mirza MR; Matulonis UA Gynecol Oncol; 2018 Apr; 149(1):214-220. PubMed ID: 29397193 [TBL] [Abstract][Full Text] [Related]
6. Niraparib: A Review in Ovarian Cancer. Heo YA; Duggan ST Target Oncol; 2018 Aug; 13(4):533-539. PubMed ID: 30073633 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of absorption, distribution, metabolism, and excretion of [ Liao M; Watkins S; Nash E; Isaacson J; Etter J; Beltman J; Fan R; Shen L; Mutlib A; Kemeny V; Pápai Z; van Tilburg P; Xiao JJ Invest New Drugs; 2020 Jun; 38(3):765-775. PubMed ID: 31250355 [TBL] [Abstract][Full Text] [Related]
8. Niraparib: First Global Approval. Scott LJ Drugs; 2017 Jun; 77(9):1029-1034. PubMed ID: 28474297 [TBL] [Abstract][Full Text] [Related]
9. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial. Mirza MR; Benigno B; Dørum A; Mahner S; Bessette P; Barceló IB; Berton-Rigaud D; Ledermann JA; Rimel BJ; Herrstedt J; Lau S; du Bois A; Herráez AC; Kalbacher E; Buscema J; Lorusso D; Vergote I; Levy T; Wang P; de Jong FA; Gupta D; Matulonis UA Gynecol Oncol; 2020 Nov; 159(2):442-448. PubMed ID: 32981695 [TBL] [Abstract][Full Text] [Related]
10. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Sandhu SK; Schelman WR; Wilding G; Moreno V; Baird RD; Miranda S; Hylands L; Riisnaes R; Forster M; Omlin A; Kreischer N; Thway K; Gevensleben H; Sun L; Loughney J; Chatterjee M; Toniatti C; Carpenter CL; Iannone R; Kaye SB; de Bono JS; Wenham RM Lancet Oncol; 2013 Aug; 14(9):882-92. PubMed ID: 23810788 [TBL] [Abstract][Full Text] [Related]
11. Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Kerliu L; Myruski S; Bhatti A; Soni P; Petrosius P; Pervanas HC; Horton ER Ann Pharmacother; 2020 Oct; 54(10):1010-1015. PubMed ID: 32172572 [TBL] [Abstract][Full Text] [Related]
12. Niraparib for the treatment of ovarian cancer. Essel KG; Moore KN Expert Rev Anticancer Ther; 2018 Aug; 18(8):727-733. PubMed ID: 29911447 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer. Longoria TC; Tewari KS Expert Opin Drug Metab Toxicol; 2018 May; 14(5):543-550. PubMed ID: 29620474 [TBL] [Abstract][Full Text] [Related]
14. The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer. Moore K; Zhang ZY; Agarwal S; Burris H; Patel MR; Kansra V Cancer Chemother Pharmacol; 2018 Mar; 81(3):497-503. PubMed ID: 29322231 [TBL] [Abstract][Full Text] [Related]
15. Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. Moore K; Chan JK; Secord AA; Patel MR; Callahan T; Guo W; Zhang ZY Cancer Chemother Pharmacol; 2019 Apr; 83(4):717-726. PubMed ID: 30680521 [TBL] [Abstract][Full Text] [Related]